Streetbeat News

Analyst Ratings

RAMP

Morgan Stanley analyst Stan Zlotsky has maintained an Overweight rating on LiveRamp Holdings (NYSE:RAMP) and raised the price target from $37 to $40.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:22 pm

CDNA

Stephens & Co. analyst Mason Carrico has upgraded CareDx (NASDAQ:CDNA) from Equal-Weight to Overweight and set a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:20 pm

KRNT

Morgan Stanley analyst Erik Woodring has maintained an Overweight rating on Kornit Digital (NASDAQ:KRNT) but lowered the price target from $29 to $24.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:20 pm

NKTR

TD Cowen analyst Chris Shibutani has upgraded Nektar Therapeutics from Market Perform to Outperform.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:18 pm

K

Morgan Stanley analyst Pamela Kaufman maintains an Equal-Weight rating on Kellanova (NYSE:K) and has lowered the price target from $68 to $57.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:18 pm

JXN

Morgan Stanley analyst Nigel Dally has maintained an Equal-Weight rating on Jackson Finl (NYSE:JXN) and raised the price target from $34 to $35.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:16 pm

WOW

WideOpenWest reported worse-than-expected Q3 sales results, leading to a downgrade of the stock from Overweight to Sector Weight by Keybanc. This has resulted in a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:16 pm

VFF

Craig-Hallum analyst Eric Des Lauriers has upgraded Village Farms Intl (NASDAQ:VFF) from Hold to Buy.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:15 pm

MDNA

MDNAF

Medicenna Therapeutics Corp. (TSX:MDNA, OTC:MDNAF) will present long-term follow-up data from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55) at the Society for Neuro-Oncology 2023 Annual Meeting. The data shows that bizaxofusp more than doubled the median survival in end-stage recurrent glioblastoma patients. The company is actively pursuing potential partnerships to conduct the Phase 3 LIGHT trial and commercialize bizaxofusp in key global markets.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:15 pm

KRNT

Craig-Hallum analyst Greg Palm has upgraded Kornit Digital (NASDAQ:KRNT) from Hold to Buy and announced a $23 price target.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:13 pm